NeoImmuneTech (A950220) Q4 2025 earnings summary

Executive summary

• Focused on T cell-based immunotherapy R&D, with NT-I7 as the core pipeline and expansion into rare disease treatments via Endari® licensing for North America.

• 2025 saw a narrowed operating loss of $17.7M and net loss of $22.4M, both significantly reduced from 2024.

• Strengthened financial position with a 46% increase in equity to $41.3M, driven by capital raises and convertible bond conversions.

• Maintained robust liquidity with $35M in cash and equivalents at year-end.

Financial highlights

• Revenue: $66.7K, primarily from R&D service contracts; no product sales yet.

• Operating loss: $17.7M, a 40% improvement year-over-year.

• Net loss: $22.4M, a 25% improvement year-over-year.

• R&D expenses: $12.1M, down 41% from 2024, reflecting clinical trial completions.

• Equity: $41.3M (+46% YoY); debt ratio improved to 38.6%.

Outlook and guidance

• Anticipates first commercial revenue from Endari® in North America starting 2026.

• Expects product revenue from NT-I7 after FDA approval for ARS or successful out-licensing.

• Continues to pursue licensing, partnerships, and government supply contracts for pipeline assets.